💊 Methadone vs buprenorphine: which opioid pharmacotherapy is right? ✨

Methadone and buprenorphine are the two pillars of opioid pharmacotherapy in Australia. Both have strong evidence, both reduce mortality from opioid dependence dramatically, and both have very different daily realities. The choice between them is rarely about which is "better" overall — it is about which fits a specific person's life, body, and goals.

Why pharmacotherapy at all

Opioid dependence — heroin, oxycodone, fentanyl, codeine — produces some of the most stubborn neurobiological adaptations in addiction medicine. The endogenous opioid system, which regulates pain, mood, and reward, is comprehensively rewired by sustained use. Cravings can be intense for months or years after a person stops, and the relapse rate without pharmacotherapy is notoriously high.

Pharmacotherapy addresses this directly. Both methadone and buprenorphine occupy opioid receptors in a controlled, long-acting way that prevents withdrawal, blocks cravings, and reduces the high from any non-prescribed opioids on top. The combined evidence — Australian and international — shows pharmacotherapy reduces mortality from opioid dependence by roughly half, reduces transmission of HIV and hepatitis C, reduces criminal activity, and improves work and family stability. Few interventions in medicine have an evidence base this strong.

The Australian Pharmaceutical Benefits Scheme (PBS) covers both medications under the Opioid Dependence Treatment Program. Roughly 55,000 Australians are currently in opioid pharmacotherapy.

Methadone in plain English

Methadone is a full opioid agonist — meaning it activates opioid receptors fully, the same way heroin or morphine do, but with a much longer half-life (24-36 hours) and a flat plasma curve that prevents the rapid spikes that produce a high. Taken once daily as a syrup or tablet, it holds withdrawal off and prevents craving for the full day.

Strengths. Highly effective for severe dependence, particularly in people who have used opioids heavily for many years. Predictable, well-understood, decades of clinical experience. Works well for people who have tried buprenorphine and not held a stable dose. Tolerates a wide therapeutic range — doses from 60mg to 120mg per day are common, with some people stable above that.

Limitations. Initial induction is delicate — methadone takes several days to reach steady state, and overdose risk in the first two weeks is meaningfully higher than in any other phase. Daily supervised dosing at a pharmacy or clinic is the norm at the start, which is a substantial daily commitment. Interacts with a long list of other medications. QT-interval prolongation (a heart-rhythm risk) at higher doses, requiring ECG monitoring. Coming off methadone is slow — usually months — and many people find the final taper from low doses (20mg down to zero) the hardest part.

Buprenorphine in plain English

Buprenorphine is a partial opioid agonist — meaning it activates opioid receptors only partially, with a "ceiling effect" beyond which more dose does not produce more effect. This is what makes it dramatically safer than methadone in overdose: a person on buprenorphine alone cannot easily die from too much of it, in the way they can with methadone. Most Australian buprenorphine prescribing now is the long-acting depot form (see the separate guide), but daily sublingual buprenorphine — taken under the tongue — remains a mainstay.

Strengths. Significantly safer overdose profile. Easier to come off than methadone, with shorter taper times. Less interaction with other medications. Works well for moderate dependence and for people who want a treatment that interferes less with daily life. The combination product Suboxone (buprenorphine + naloxone) adds a built-in disincentive against injecting the medication.

Limitations. Induction requires a person to be in mild-to-moderate withdrawal before the first dose — taking buprenorphine while still loaded with full agonists like heroin or fentanyl can precipitate a sharp, unpleasant withdrawal. For very heavy or long-term users, particularly those using fentanyl, the partial agonism can be insufficient — the person feels under-medicated and craves on top. Sublingual administration takes 5-10 minutes of holding the tablet under the tongue, which some people find difficult.

How prescribers actually decide

A few patterns from Australian addiction medicine practice.

Severity and history. Heavier and longer-term opioid use, particularly of high-potency opioids like fentanyl or pharmaceutical-grade oxycodone, often pushes toward methadone. Less severe or shorter-duration dependence often does well on buprenorphine.

Other medications. If a person is on medications that interact significantly with methadone (some antiretrovirals, some psychiatric medications, some antibiotics), buprenorphine is often preferred.

Cardiac risk. Methadone can prolong the QT interval, which raises arrhythmia risk. People with cardiac disease, on other QT-prolonging medications, or with electrolyte abnormalities are usually steered toward buprenorphine.

Practical life. Buprenorphine is generally easier to live a full life on — daily dosing flexibility is greater, side effects are typically milder, and the long-acting depot forms eliminate the daily tablet entirely. For working people, parents, students, and people in regional areas where pharmacy supervision is logistically hard, this matters.

Patient preference. Both medications work. Patient preference, when informed, is a legitimate part of the decision and predicts retention in treatment.

How daily life looks on each

On methadone, most people in the early months attend a pharmacy or clinic daily for supervised dosing. This commitment relaxes over time as the person stabilises — first to a few takeaway doses per week, then more — but it is real, particularly in the first six to twelve months. Some people find the routine grounding; others find it constraining.

On daily sublingual buprenorphine, supervised dosing is typical at the start but transitions to takeaway dosing more rapidly than methadone in many cases. On long-acting depot buprenorphine (Sublocade or Buvidal), the entire daily-medication piece disappears — replaced by a weekly or monthly injection at the prescriber's clinic.

Coming off

Both medications can be tapered. Methadone tapering is slow — typically 5-10mg reductions every few weeks, with extended periods at low doses. The final taper from 30mg to zero is often the hardest, and some people find a brief switch to buprenorphine at the very end smooths it out.

Buprenorphine tapering is generally faster and better tolerated. Reductions of 2-4mg every few weeks are common; many people taper to zero over three to six months once they are ready.

A core point: there is no clinical reason to taper before the person is ready. The evidence is clear that staying on pharmacotherapy long-term is associated with substantially better outcomes — including lower mortality — than tapering off prematurely. For some people, lifelong pharmacotherapy is the right answer, and that is a legitimate clinical choice.

How to access opioid pharmacotherapy in Australia

Three main pathways.

Public AOD services. Each state has a public opioid pharmacotherapy program, usually accessed via the state alcohol and drug line or a community AOD intake service. Free or low-cost (small dispensing fee at the pharmacy). Most have current capacity, though wait times for specific clinics vary.

Public hospital addiction services. For complex cases, people coming out of hospital, or people needing inpatient stabilisation, the public hospital addiction medicine units in capital cities are the right pathway.

Private addiction medicine specialists and accredited GPs. Any GP in Australia can become an authorised pharmacotherapy prescriber. The number of GPs offering this is growing but uneven across regions. Private addiction medicine specialists are concentrated in capital cities and accept private and Medicare-rebated consultations. Cost is moderate — typical out-of-pocket consultation costs of $80-$200 — and gives shorter wait times and more flexible care.

The current best resource for finding a prescriber is the Australian Department of Health AOD service finder and your state's alcohol and drug line. The pharmacotherapy itself is PBS-listed and the per-script cost is small.